High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
about
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II studyOptimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccinesIdentification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis.Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic miceHighly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.Telomerase as a tumor-associated antigen for cancer immunotherapyPeptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvantCD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patientsVaccine-induced Aβ-specific CD8+ T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease.Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.HLA class I transgenic mice: development, utilisation and improvement.Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come.Towards a therapeutic breast cancer vaccine: the next steps.The tumor-draining lymph node as an immune-privileged site.Telomerase-based immunotherapy of cancer.'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.A review of vaccine clinical trials for non-small cell lung cancer.Promises and limitations of murine models in the development of anticancer T-cell vaccines.Weak proinsulin peptide-major histocompatibility complexes are targeted in autoimmune diabetes in mice.Quantitative theories of T-cell responsiveness.Identification of T-cell epitopes for cancer immunotherapy.Mobilizing the low-avidity T cell repertoire to kill tumors.Prospects and challenges of building a cancer vaccine targeting telomeraseTARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer.Improving T cell responses to modified peptides in tumor vaccinesIs telomerase a viable target in cancer?Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.Towards in silico design of epitope-based vaccines.Analogue peptides for the immunotherapy of human acute myeloid leukemia.Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic miceType 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptidesHierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.Mannan-modified adenovirus as a vaccine to induce antitumor immunity.EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.
P2860
Q24652592-D16D0CA6-DB1E-4FA3-8446-4038C4118B3AQ26738680-116A06FF-4984-4E0D-A0C1-796F4213B8C4Q30418879-2B07D1FE-5405-4002-9436-3756B0D68069Q33276030-22D221EC-64DC-4E1B-9C12-B5450CD51704Q33522216-3D15D98C-81D6-4D52-AEFE-6255BF4847B2Q33897405-93CE23DE-9D09-483F-A09F-285F7C8D7F45Q34878113-17C65570-4F31-4DF4-BBBF-82D8C3F4E084Q35125382-83C336E0-5153-472C-8B82-BDE52CF4750BQ35588533-31C89085-B7ED-4E07-86EB-7FE53C373E3CQ35663042-11CE634F-4094-4BD6-BD17-EDE82AE04844Q35848862-BC47908A-F6CE-43E1-B18B-15588A1F268CQ36194073-36B0F9D8-2F67-4F38-88AE-5F1AF1A2A994Q36331221-C2BA8404-130B-4765-88F7-91093D0E0885Q36350565-5861E4CD-6C37-486C-9578-7BC07D35C1E0Q36593753-82AC9600-6D5C-4878-8777-E272FB66C0F5Q36600251-8A7964FA-D519-4767-AAFC-B5739FDA377EQ36610764-B86282B8-CA11-403F-8EBF-34C9B8615493Q36653524-F98586D3-30FF-4E9E-AD91-86C40AED7CF8Q36675454-819EB591-A4B0-4805-8755-72EC247A510FQ36684482-462737A5-DF85-490D-B601-8EB647FE6CFCQ36756575-BE757C52-8D40-46DB-BFC9-B26F8B2CC27BQ36762522-29DA86CF-31F1-4501-814A-990C40FAE0F3Q36870592-1DFBCE13-A012-4EAA-9F74-ECB17EB23FF6Q36891310-91B84355-77E5-4834-A683-D9D30A5D3342Q36918394-5131BCEF-D6CD-484C-8304-70DB3BA65025Q37224581-0945BF1E-67F4-462D-BDFC-FD8404F0AC3EQ37634253-222AC345-10A9-4EF4-BFD0-40B69D072210Q37908470-2C0F5293-55C3-4851-9A6B-1C306DAB2A55Q38077405-79C0FAF5-168C-46B1-AFE1-C10453CC1B38Q38088325-4519501D-584D-4AF8-95A6-4BC5CEF40FF0Q38599586-18669FF7-13FA-4E58-8F2F-DBFCF7137DD5Q38706572-150A04CF-F2EA-426C-9BDB-A7546C0C7619Q38808868-5ED8BD3F-2A88-4AB7-9493-A8B97B6B65F0Q39285795-553C483C-E92A-44A9-97C8-8FE053A46ABBQ39882401-13982163-4F28-42F8-B047-48D8EC72913CQ40215247-5EFA175E-2350-4623-819A-FC4E9EF680E8Q40243921-AD845A95-60F2-4CCA-8AC7-C045D3F0D3ADQ40365151-128A5B88-6CD5-4AB4-A407-6C677A4035D4Q40418904-4796446E-1DB2-4DD5-80E8-A91D67BE331FQ40510640-637E79A7-B9E3-4160-9898-75124BC4EF8E
P2860
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
@ast
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
@en
type
label
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
@ast
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
@en
prefLabel
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
@ast
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.
@en
P2093
P2860
P50
P356
P1476
High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
@en
P2093
François A Lemonnier
Hüseyin Firat
Isabelle Miconnet
Kostas Kosmatopoulos
Olivier Faure
Paule Opolon
Pedro Alves
Philippe Guillaume
Robert H Vonderheide
Salem Chouaib
P2860
P304
P356
10.1172/JCI200419418
P407
P577
2004-02-01T00:00:00Z